SEMA6A inhibits tumor progression and boosts anti-tumor immunity via blocking the ISG15/TGFβ axis in colorectal cancer
Fang Zhang, Rixin Zhang, Zheng Yan, Jinbao Zong, Mingxuan Zhou, Tiegang Li, Yufang Hou, Silin Lv, Zifan Zeng, Wenyi Zhao, Yixin Zhou, Zengni Zhu, Siying Huang, Min Yang · 2026
Read SEMA6A inhibits tumor progression and boosts anti-tumor immunity via blocking the ISG15/TGFβ axis in colorectal cancer by Fang Zhang, Rixin Zhang, Zheng Yan, Jinbao Zong, Mingxuan Zhou, Tiegang Li, Yufang Hou, Silin Lv, Zifan Zeng, Wenyi Zhao, Yixin Zhou, Zengni Zhu, Siying Huang, Min Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13272749.txt.
Description
Fang Zhang leads a 2026 study of a protein called SEMA6A in colorectal cancer, cancer of the colon and rectum. The protein was lower in cancer tissue than normal, and low levels linked to more aggressive tumors and a poorer outlook. The team tested what raising SEMA6A does in cells and in animals.
Raising SEMA6A slowed tumors and boosted killing by CD8 T cells, the immune cells that attack cancer. It acted by lowering a protein called ISG15, which otherwise helps stabilize TGF-beta, a signal that shields tumors. Patients with high SEMA6A and low ISG15 responded better to immunotherapy, and raising SEMA6A improved anti-PD-1 treatment in mice.
Catalog record
| CREATOR | Fang Zhang, Rixin Zhang, Zheng Yan, Jinbao Zong, Mingxuan Zhou, Tiegang Li, Yufang Hou, Silin Lv, Zifan Zeng, Wenyi Zhao, Yixin Zhou, Zengni Zhu, Siying Huang, Min Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50429 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |